SIGLEC10 and hepatocellular carcinoma: Block Siglec‐10 expressed by TAM, decrease expression of immunosuppressive molecules, and increase the cytotoxic effects of CD8+ T cells against HCC cells, leading to promoting the anti‐tumor efficacy of the PD‐1 inhibitor pembrolizumab